ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership who proved their scientific excellence and financiers with deep understanding of pharma business.

Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer

Jacky Vonderscher

  • Founder of Vonderscher&Co GmbH
  • Senior executive with a broad R&D experience in the pharmaceutical industry
  • Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
  • Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
  • Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
  • Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
  • Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
  • Board member of Inatherys, Step Pharma and ObsEva and SAB member of Inotrem SA
  • Board member of LyonBiopôle and IMI-JU (Innovative Medicines Initiative-Joint Undertaking)

Dr Pietro Scalfaro, MD, MBA, SVP Head of Clinical Development Chief Medical Officer

Pietro Scalfaro

  • In charge of strategy and operational management of the clinical drug programs
  • Wide range experience in various roles in the healthcare sector, working notably in infectious diseases (HCV, via the development of Alisporivir), septicaemia, oncology, Alzheimer’s disease and cardio-respiratory diseases
  • Set up a Personalised Medicine Business Unit at Debiopharm Group and involved during start-up of eHealth and diagnostic companies (Biocartis, Sophia Genetics, Agendia, Immunexpress, Pryv, Orphanalytics)
  • Practicing physician, with degrees from the University of Lausanne and the Swiss Medical Association in Paediatrics, Intensive Care and MBA

Dr Raphaël Darteil, PhD, SVP Head of non-clinical Development & Profiling

Raphaël Darteil

  • Responsible for non-clinical development and in vitro / in vivo compound profiling
  • More than 20 years of experience in R&D project and portfolio management in the Pharma and Biotech industries
  • Scientific expertise in metabolic diseases (including NAFLD/NASH) and in the Nuclear Receptor field
  • COO and Member of the board at Genfit
  • Various positions in the department of Gene Therapy of Aventis both in France and in the US
  • Co-inventor of the patent protecting the use of Elafibranor (Phase III) for the treatment of NASH patients
  • He owns a PhD in Molecular and Cellular Biology from the University Claude Bernard Lyon I

Keltoum Medji, MBA, VP Finance and Strategic Development

Keltoum Medji

  • Responsible for all finance activities including fundraising, investors relations, strategic partnerships
  • More than 20 years’ experience in Orthopedic business supporting growth by an increased collaboration with supply chain & commercial organizations
  • Strong experience in change management through diverse organizational changes as M&A, restructuring, reorganizations
  • Graduated with a Master’s degree in Economics & Business Management and an MBA from EM Lyon Business School

Claudi Miquel, VP Legal Affairs & Board Secretary

Claudi Miquel

  • Responsible for all legal affairs and Secretary of the Board of Directors
  • 15 years’ experience as an attorney as well as lead counsel for international organizations across different jurisdictions
  • Experience in transactional, financing, IP, and corporate/governance matters
  • Graduated with a master’s degree in business law from Vanderbilt University law school

Pete Leone, MBA, Head of Business Development & Licensing

Pete Leon

  • Responsible for Business development
  • More than 30 years of C-level experience at public and private biopharmaceutical companies, with over $6 billion in upfront payments and potential milestones from business development transactions that he led to closure
  • Various management roles at Arrowhead Pharmaceuticals (Nasdaq: ARWR), including business development, was CBO at Bicycle Therapeutics (Nasdaq: BCYC), and previously, a cofounder of three venture-backed companies, including Mersana Therapeutics (Nasdaq: MRSN)
  • Corporate and not-for-profit board member, including SeromYx Systems, Third Monday Foundation, and Nuestros Pequeños Hermanos – NPH USA Northeast region
  • Holds an A.B. in engineering science with pre-med studies from Dartmouth College and an MBA from the Stanford University Graduate School of Business